Zacks Research Upgrades Hemab Therapeutics (NASDAQ:COAG) to Hold

Hemab Therapeutics (NASDAQ:COAG) was upgraded by equities research analysts at Zacks Research to a “hold” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

Several other research analysts have also issued reports on COAG. The Goldman Sachs Group initiated coverage on Hemab Therapeutics in a research report on Tuesday. They set a “buy” rating and a $36.00 target price for the company. Jefferies Financial Group initiated coverage on Hemab Therapeutics in a research report on Tuesday. They set a “buy” rating and a $39.00 target price for the company. Wall Street Zen raised Hemab Therapeutics to a “hold” rating in a research report on Saturday, May 9th. Wedbush initiated coverage on Hemab Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $42.00 target price for the company. Finally, Evercore initiated coverage on Hemab Therapeutics in a research report on Tuesday. They set an “outperform” rating and a $50.00 target price for the company. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $41.75.

Hemab Therapeutics Trading Down 2.1%

NASDAQ COAG opened at $28.00 on Wednesday. Hemab Therapeutics has a twelve month low of $23.00 and a twelve month high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last announced its earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insider Activity at Hemab Therapeutics

In other news, major shareholder Ra Capital Management, L.P. bought 3,802 shares of Hemab Therapeutics stock in a transaction dated Tuesday, May 19th. The stock was bought at an average cost of $24.97 per share, for a total transaction of $94,935.94. Following the purchase, the insider directly owned 6,375,972 shares in the company, valued at approximately $159,208,020.84. This represents a 0.06% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last three months, insiders bought 2,902,872 shares of company stock valued at $53,769,784.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.